Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients

Shaji K Kumar, Angela Dispenzieri, Martha Lacy, Morie Gertz, F. K. Buadi, S. Pandey, Prashant Kapoor, David M Dingli, S. R. Hayman, N. Leung, J. Lust, A. McCurdy, Stephen J Russell, S. R. Zeldenrust, R. A. Kyle, S Vincent Rajkumar

Research output: Contribution to journalArticle

591 Citations (Scopus)

Abstract

Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The median estimated follow-up for the cohort was 5.9 years with 47% alive at the last follow-up. The median overall survival (OS) for the entire cohort was 5.2 years: 4.6 years for patients in the 2001-2005 group compared with 6.1 years for the 2006-2010 cohort (P=0.002). The improvement was primarily seen among patients over 65 years, the 6-year OS improving from 31 to 56%, P<0.001. Only 10% of patients died during the first year in the latter group, compared with 16% in the earlier cohort (P<0.01), suggesting improvement in early mortality. The improved outcomes were linked closely to the use of one or more new agents in initial therapy. The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.

Original languageEnglish (US)
Pages (from-to)1122-1128
Number of pages7
JournalLeukemia
Volume28
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Multiple Myeloma
Survival
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • immunomodulatory
  • multiple myeloma
  • proteasome inhibitors
  • survival

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Continued improvement in survival in multiple myeloma : Changes in early mortality and outcomes in older patients. / Kumar, Shaji K; Dispenzieri, Angela; Lacy, Martha; Gertz, Morie; Buadi, F. K.; Pandey, S.; Kapoor, Prashant; Dingli, David M; Hayman, S. R.; Leung, N.; Lust, J.; McCurdy, A.; Russell, Stephen J; Zeldenrust, S. R.; Kyle, R. A.; Rajkumar, S Vincent.

In: Leukemia, Vol. 28, No. 5, 2014, p. 1122-1128.

Research output: Contribution to journalArticle

@article{89797271a9744ef488a99650fd49d240,
title = "Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients",
abstract = "Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The median estimated follow-up for the cohort was 5.9 years with 47{\%} alive at the last follow-up. The median overall survival (OS) for the entire cohort was 5.2 years: 4.6 years for patients in the 2001-2005 group compared with 6.1 years for the 2006-2010 cohort (P=0.002). The improvement was primarily seen among patients over 65 years, the 6-year OS improving from 31 to 56{\%}, P<0.001. Only 10{\%} of patients died during the first year in the latter group, compared with 16{\%} in the earlier cohort (P<0.01), suggesting improvement in early mortality. The improved outcomes were linked closely to the use of one or more new agents in initial therapy. The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.",
keywords = "immunomodulatory, multiple myeloma, proteasome inhibitors, survival",
author = "Kumar, {Shaji K} and Angela Dispenzieri and Martha Lacy and Morie Gertz and Buadi, {F. K.} and S. Pandey and Prashant Kapoor and Dingli, {David M} and Hayman, {S. R.} and N. Leung and J. Lust and A. McCurdy and Russell, {Stephen J} and Zeldenrust, {S. R.} and Kyle, {R. A.} and Rajkumar, {S Vincent}",
year = "2014",
doi = "10.1038/leu.2013.313",
language = "English (US)",
volume = "28",
pages = "1122--1128",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Continued improvement in survival in multiple myeloma

T2 - Changes in early mortality and outcomes in older patients

AU - Kumar, Shaji K

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Gertz, Morie

AU - Buadi, F. K.

AU - Pandey, S.

AU - Kapoor, Prashant

AU - Dingli, David M

AU - Hayman, S. R.

AU - Leung, N.

AU - Lust, J.

AU - McCurdy, A.

AU - Russell, Stephen J

AU - Zeldenrust, S. R.

AU - Kyle, R. A.

AU - Rajkumar, S Vincent

PY - 2014

Y1 - 2014

N2 - Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The median estimated follow-up for the cohort was 5.9 years with 47% alive at the last follow-up. The median overall survival (OS) for the entire cohort was 5.2 years: 4.6 years for patients in the 2001-2005 group compared with 6.1 years for the 2006-2010 cohort (P=0.002). The improvement was primarily seen among patients over 65 years, the 6-year OS improving from 31 to 56%, P<0.001. Only 10% of patients died during the first year in the latter group, compared with 16% in the earlier cohort (P<0.01), suggesting improvement in early mortality. The improved outcomes were linked closely to the use of one or more new agents in initial therapy. The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.

AB - Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The median estimated follow-up for the cohort was 5.9 years with 47% alive at the last follow-up. The median overall survival (OS) for the entire cohort was 5.2 years: 4.6 years for patients in the 2001-2005 group compared with 6.1 years for the 2006-2010 cohort (P=0.002). The improvement was primarily seen among patients over 65 years, the 6-year OS improving from 31 to 56%, P<0.001. Only 10% of patients died during the first year in the latter group, compared with 16% in the earlier cohort (P<0.01), suggesting improvement in early mortality. The improved outcomes were linked closely to the use of one or more new agents in initial therapy. The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.

KW - immunomodulatory

KW - multiple myeloma

KW - proteasome inhibitors

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84899977355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899977355&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.313

DO - 10.1038/leu.2013.313

M3 - Article

C2 - 24157580

AN - SCOPUS:84899977355

VL - 28

SP - 1122

EP - 1128

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -